pembrolizumab
merck
[]
the latest in hepatocellular carcinoma trials, presented at #gi23 and brought to you by #noeticinsight phase 2 immulab has evidence of safety &amp; efficacy against early disease of peri-interventional pembrolizumab + local radiofrequency/microwave ablation or brachytherapy. 